Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06603220 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
A Phase 2 study, sponsored by Evommune.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT06603220 is a Phase 2 study that has completed, run by Evommune. The registered enrollment target is 30 participants.
The verdict
NCT06603220, a Phase 2 study, has completed, sponsored by Evommune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
Interventions
- DRUG Oral EVO756 300 mg QD
- DRUG Oral EVO756 50 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2025-05-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06603220
The ClinicalTrials.gov registry entry for NCT06603220 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Evommune, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oral EVO756 300 mg QD is the first listed.
NCT06603220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06603220 about?
NCT06603220 is a clinical study titled "A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria". This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
What is the current status of trial NCT06603220?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-08-14. Estimated completion is 2025-05-08.
What interventions are being tested in trial NCT06603220?
The interventions under investigation include: Oral EVO756 300 mg QD (DRUG), Oral EVO756 50 mg BID (DRUG).
Who is sponsoring clinical trial NCT06603220?
This trial is sponsored by Evommune, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.